Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular …
Summary Background Glucagon-like peptide-1 (GLP-1) receptor agonists differ in their
structure and duration of action and have been studied in trials of varying sizes and with …
structure and duration of action and have been studied in trials of varying sizes and with …
[HTML][HTML] Dapagliflozin in patients with heart failure and reduced ejection fraction
JJV McMurray, SD Solomon, SE Inzucchi… - … England Journal of …, 2019 - Mass Medical Soc
Background In patients with type 2 diabetes, inhibitors of sodium–glucose cotransporter 2
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
(SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose …
Sacubitril/valsartan: neprilysin inhibition 5 years after PARADIGM-HF
KF Docherty, M Vaduganathan, SD Solomon… - Heart Failure, 2020 - jacc.org
Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), has been shown to
reduce the risk of cardiovascular death or heart failure hospitalization and improve …
reduce the risk of cardiovascular death or heart failure hospitalization and improve …
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Background SGLT2 inhibitors are strongly recommended in guidelines to treat patients with
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …
heart failure with reduced ejection fraction, but their clinical benefits at higher ejection …
Statin treatment of children with familial hypercholesterolemia–trying to balance incomplete evidence of long-term safety and clinical accountability: are we …
A Vuorio, KF Docherty, SE Humphries, J Kuoppala… - Atherosclerosis, 2013 - Elsevier
In the heterozygous form of familial hypercholesterolemia (FH), blood concentrations of low-
density lipoprotein cholesterol (LDL-C) are elevated two to three times above the normal …
density lipoprotein cholesterol (LDL-C) are elevated two to three times above the normal …
[HTML][HTML] Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER
Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)
Background: Sodium-glucose cotransporter 2 inhibitors reduce the risk of heart failure
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
hospitalization and cardiovascular death in patients with heart failure and reduced ejection …
Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF
Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …
chronic kidney disease that complicates pharmacological management and is associated …
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF
JP Curtain, KF Docherty, PS Jhund… - European heart …, 2021 - academic.oup.com
Aims The aim of this study was to examine the effect of dapagliflozin on the incidence of
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …
ventricular arrhythmias and sudden death in patients with heart failure and reduced ejection …